GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to ...

UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...

GSK said it expects to take a charge of £1.8 billion ($2.3 billion) in its third-quarter results in relation to the ...

The British drugmaker reached a $2.2 billion settlement to resolve around 80,000 lawsuits over claims its Zantac heartburn ...

The first lawsuit claiming that gastrointestinal drug Zantac causes cancer has been ... early 1980s and sold it as a prescription and over-the-counter (OTC) product for indications like heartburn ...

GSK (GSK) on Wednesday announced a settlement resolving a bundle of 80,000 product liability cases in the US that alleged its over-the-counter heartburn medication, Zantac, increased the risk of ...

Ranitidine products are used to reduce the production of stomach acid in patients with conditions such as heartburn and stomach ulcers. They are available over-the-counter and on prescription.

GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its ...

The agency cited concerns that ranitidine could degrade into NDMA, a carcinogen, over time or when exposed to heat. Pfizer has agreed to settle most of the Zantac cases against it in state court ...

A fourth Chicago jury failed to award damages to cancer victims suing a manufacturer of over-the-counter heartburn medication Zantac, but the first trial in California is ramping up. On Wednesday ...

The agency cited concerns that ranitidine could degrade into NDMA, a carcinogen, over time or when exposed to heat. Pfizer has agreed to settle most of the Zantac cases against it in state court ...